Efficacy and safety of anti-PD-1/anti-PD-L1 antibody therapy in treatment of advanced gastric cancer or gastroesophageal junction cancer: A meta-analysis

Li Yang, Xian-Zhe Dong, Xiao-Xuan Xing, Xiao-Hui Cui, Lin Li, Lan Zhang

ORCID numbers: Li Yang 0000-0001-8257-6094; Xian-Zhe Dong 0000-0002-5286-4623; Xiao-Xuan Xing 0000-0002-6792-4967; Xiao-Hui Cui 0000-0001-6905-8866; Lin Li 0000-0001-9218-1045; Lan Zhang 0000-0002-5220-3171.

Author contributions: Yang L and Dong XZ designed the study and wrote the manuscript; Yang L and Xing XX conducted the literature search; Yang L and Dong XZ collected and retrieved the data; Yang L and Cui XH analyzed the data; Dong XZ, Li L, and Zhang L critically reviewed and revised the manuscript; and all authors proofread the manuscript.

Supported by: Beijing Hospitals Authority Ascent Plan, No. DFL20190803; Capital Science and Technology Leading Talent Training Project, No. Z19110000619017; National Nature and Science Foundation of China, No. 81773778; and China Postdoctoral Science Foundation, No. 2019M650775.

Conflict-of-interest statement: No conflict of interest.

PRISMA 2009 Checklist statement: The authors have read the PRISMA 2009 Checklist, and the manuscript was prepared and revised.

Abstract

BACKGROUND
Faced with limited and inadequate treatment options for patients with advanced gastric cancer or gastroesophageal junction cancer (GC/GEJC), researchers have turned toward, with the support of promising clinical trials, anti-PD-1/anti-PD-L1 antibody therapy. But there are also different clinical trial results. To better assess its efficacy and safety, we integrated data from 13 eligible studies for a systematic review and meta-analysis.

AIM
To comprehensively evaluate the efficacy and safety of anti-PD-1/anti-PD-L1 antibody therapy in the treatment of advanced GC/GEJC patients.

METHODS
PubMed, Web of Science, Cochrane Library, and EMBASE databases were searched to identify eligible articles with outcomes including objective response rate (ORR), disease control rate (DCR), overall survival (OS), progression-free survival (PFS), and adverse events (AEs) of anti-PD-1/anti-PD-L1 antibody therapy.

RESULTS
Our study encompassed a total of 13 trials totaling 1618 patients. The outcomes...
Gastric cancer (GC/GEJC) continue to deteriorate after treatments, most patients with advanced gastric cancer or gastroesophageal junction (PS) 0-1 as the second-line treatment fluorouracil chemotherapy for HER-2 positive patients as the first-line treatment (HER-2) negative patients, and trastuzumab in combination with platinum and platinum/fluorouracil combinations for human epidermal growth factor receptor 2 patients with advanced chemotherapy, with especially poor prognosis and overall survival (OS) rate for approximately metastatic tumor, bringing the 5-year survival rate from less than globally, there were still 1033701 new GC cases and 782685 death counts in 2018, with cause of cancer death worldwide. Although GC incidence has been declining globally, there were still 1033701 new GC cases and 782685 death counts in 2018, with overall half occurring in East Asia, especially China. Because GC patients often present nonspecific symptoms, diagnosis occurs predominantly at an advanced stage, where approximately 50% of patients have already developed locally advanced or metastatic tumor, bringing the 5-year survival rate from less than 30% down to approximately 15%.

Current, the primary treatment option for GC patients is surgery and chemotherapy, with especially poor prognosis and overall survival (OS) rate for patients with advanced GC. Current clinical guidelines recommend dual or triple platinum/fluorouracil combinations for human epidermal growth factor receptor 2 (HER-2) negative patients, and trastuzumab in combination with platinum and fluorouracil chemotherapy for HER-2 positive patients as the first-line treatment options, and taxanes, irinotecan, or ramucirumab for patients with performance status (PS) 0-1 as the second-line treatment options. Nevertheless, despite these treatments, most patients with advanced gastric cancer or gastroesophageal junction cancer (GC/GEJC) continue to deteriorate after treatment.

Immune checkpoint inhibitors, such as PD-1 and PD-L1 inhibitors, have become the
first-line treatment for multiple malignancies\cite{15}. Inhibition of PD-1 and PD-L1 enhances the in vitro response of T cells as well as the antitumor activity in preclinical models\cite{16,17}. The phase I studies with anti-PD-1 drugs, such as nivolumab and pembrolizumab, in non-small-cell lung cancer (NSCLC), advanced melanoma, renal cell carcinoma (RCC), and other solid tumor patients have demonstrated very promising response with controlled side effects. Inspired from results, PD-1/anti-PD-L1 antibody therapies exhibiting success in many clinical trials for various types of tumors regardless of pathologic grade with long-lasting responses and tolerable toxicity\cite{18,19}. At present, the United States Food and Drug Administration (FDA) has approved PD-1 pathway inhibitors for cancer treatment including the monoclonal antibodies nivolumab (anti-PD-1; Bristol-Myers Squibb), pembrolizumab (anti-PD-1; Merck), atezolizumab (anti-PD-L1; Genentech/Rothe), avelumab (anti-PD-L1; EMD Serono/Pfizer), and durvalumab (anti-PD-L1; AstraZeneca).

Several studies have shown the prevalent overexpression of PD-L1 in GC patients, and the expression of PD-L1 plays a key role in cancer immune escape and related tumor progression and poor prognosis\cite{20,21}. Reducing the expression of PD-L1 in human gastric cancer cell line SGC-7901 can significantly inhibit cell proliferation and migration and tumor growth in subcutaneously transplanted mouse models\cite{22}. In addition, many clinical studies have initially shown that PD-L1 blockers can significantly inhibit the tumor progression of many advanced cancers such as melanoma, GC, non-small cell lung cancer, ovarian cancer and so on\cite{23,24}. Thus, anti-PD-1/anti-PD-L1 antibody therapy seemed promising as a potential approach for GC/GEJC.

In the meantime, several clinical trials have already evaluated the efficacy of anti-PD-1/anti-PD-L1 antibody therapy in advanced GC/GEJC patients, and the results show that this therapy has good anti-tumor activity and controllable adverse reactions for advanced GC/GEJC patients. However, one study suggested that not all tumors expressing PD-L1 respond to PD-1/PD-L1 inhibitors\cite{16}. And the treatment regimen has not been included in the authoritative clinical practice guidelines, such as ESMO GC diagnosis and treatment guidelines, which means that there is yet no scholarly consensus on the efficacy and safety of PD-1/PD-L1 inhibitors in the treatment of advanced GC/GEJC. To address this need, we meta-analyzed all published clinical studies based on the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) statement\cite{25}.

**MATERIALS AND METHODS**

**Systematic literature search**

PubMed, Web of Science, the Cochrane Library, and Embase were searched from inception up to March 5, 2020 using the following MeSHs headings (Gastric Cancer OR Stomach Cancer OR Stomach Neoplasm OR Gastric Neoplasm OR GC OR gastroesophageal OR Gastro Esophageal Junction Cancer OR GEJC) AND (Nivolumab OR MDX-1106 OR ONO-4538 OR BMS-936558 OR Opdivo OR Pembrolizumab OR lambrolizumab OR Keytruda OR MK-3475 OR SCH-900475 OR Atezolizumab OR anti-PDL1 OR MPDL3280A OR Tecentriq OR RG7446 OR Durvalumab OR MEDI4736 OR Imfinzi OR Avelumab OR Bavencio OR MSB0010682 OR MSB0010718C).

**Inclusion and exclusion criteria**

The literature included in this study must meet all of the following criteria: (1) Prospective clinical trials in patients with advanced GC/GEJC; (2) Patients in the immunotherapy group were treated with anti-PD-1/PD-L1 drugs; and (3) The literature provides relevant anti-tumor activity and safety data [objective response rate (ORR), disease control rate (DCR), OS, progression-free survival (PFS), adverse events (AEs), or grade ≥ 3 AEs].

The exclusion criteria for this study were as follows: (1) Conference abstracts, case reports, comments, editorials, etc.; (2) For multiple publications that have been determined to be reported in the same clinical study, the publication with the most complete publication data is qualified; and (3) The literature information was insufficient to extract the required useful data.
Selection of relevant studies
During the preliminary screening process, relevant studies were first independently selected by two authors (Yang L and Dong XZ) of this study. Any disagreements were then resolved through mutual discussion and consultation.

Data extraction
Data were extracted independently by two researchers, including the name of the first author, year of publication, trial name, trial phase, number of participants, interventions, OS, PFS, ORR, DCR, AEs, tumor characteristics, and expression level of PD-L1 (positive expression as > 1% and negative expression as ≤ 1%). Any unavailable data were recorded as “NA”.

Quality assessment
Bias risk was assessed using the Cochrane Collaboration’s tool in the following domains: Random sequence generation, allocation concealment, blinding of outcome participants and personnel, blinding of outcome assessment, incomplete outcome data, selective reporting, and other biases. Each result was classified as low risk, high risk, or unclear risk. Quality assessment was done independently by two researchers with disagreements solved through discussion.

Statistical analysis
To evaluate the efficacy of anti-PD-1/anti-PD-L1 antibody, the overall ORR and DCR as well as the combined OS and PFS rates (both 6 mo and 12 mo) were calculated. To assess its safety, the overall risk of AEs and grade ≥ 3 AEs were calculated. All statistical calculations were performed using Review Manger version 5.3 (Cochrane Collaboration’s Information Management System) and STATA version 14.0 (STATA, College Station, TX, United States). Statistical heterogeneity across studies was assessed using the Cochran Q chi-square test and the $I^2$ index. Whence significant heterogeneity was determined with either $I^2 > 50\%$ or $P$ value < 0.1, the random-effects model was applied. Sensitivity analysis was performed by removing individual studies one by one to test the reliability of the results. Publication bias was determined using Begg’s and Egger’s methods.

RESULTS

Literature search
The whole process of study selection is shown in Figure 1. Out of the 1220 initially retrieved records, 946 remained after the removal of duplicates. After the screening of titles and abstracts, 709 records were excluded and 237 were reviewed for full text. After further removal of conference reports, reviews, duplicates, and studies without clinical trials, 13 records were defined eligible.

Study characteristics
The detailed characteristics of the included studies are summarized in Table 1. The 13 eligible studies include six single-arm trials, five randomized controlled trials (RCTs), and two dose-escalation cohort expansion studies. A total of 1618 GC/GEJC patients were included, of whom 787 received pembrolizumab, 429 received nivolumab, 375 received avelumab, and 27 received durvalumab. Pembrolizumab was intravenously administered at 200 mg in five trials and 10 mg/kg in another. Nivolumab was intravenously administered at 3 mg/kg in two studies and 360 mg in another. Avelumab and durvalumab were administered at 10 mg/kg and 20 mg/kg, respectively.

Quality assessment of included studies
The quality assessment was conducted using Review Manger 5.3. Details of risk of bias for each study are presented in Figure 2. Due to the particularity of clinical trials in cancer treatment, the single-arm and dose-escalation trials are inherently considered high-risk in terms of bias. The 13 studies included in this meta-analysis were low-risk in terms of random sequence generation, allocation concealment, incomplete outcome data, and selective reporting. Blinding of outcome assessment and other biases might exist in two and four studies, respectively. Bias (blinding of outcome participants and personnel) was high risk. Generally speaking, the quality assessment of the included studies had a low risk of bias.
# Table 1 Characteristics of included studies

| Ref. | Trial | Clinical trials.gov. No. | Study design | Phase | Case, experimental vs control, (n) | Intervention methods | ORR (%) | DCR (%) | 12-mo OS (%) | 12-mo PFS (%) |
|------|-------|--------------------------|-------------|-------|----------------------------------|----------------------|---------|---------|-------------|-------------|
| Bang et al. [28] 2018 | JAVELIN Gastric 300 | NCT02625623 | RCT | III | 371, 185 vs 186 | Avelumab 10 mg/kg Q2 W vs paclitaxel 80 mg/m² or irinotecan 150 mg/m² daily 1, 8, 15 d of 4-wk cycles | 2.2 | 22.2 | NA | NA |
| Bang et al. [29] 2019 | KEYNOTE-059 (cohorts 2 and 3) | NCT02335411 | Single-arm | II | 31 | Pembrolizumab 200 mg on day 1 of 21-d cycles. | 25.8 | 35.5 | 63.0 | NA |
| Boku et al. [30] 2019 | ATTRACTION-4 | NCT02746796 | RCT | II | 40, 21 vs 19 | Nivolumab 360 mg Q3 W or SOX or Cape OX. | 65.8 | 84.2 | NA | NA |
| Chen et al. [31] 2020 | JAVELIN Gastric 300 | NCT02625623 | RCT | III | 493, 330 vs 163 | Nivolumab 3 mg/kg Q2 W vs placebo 3 mg/kg Q2 W. | 11.9 | 40.3 | 87.1 | 9.3 |
| Doi T et al. [33] 2019 | JAVELIN Solid Tumor JPN trial | NCT01943461 | Single-arm | I | 40 | Avelumab 10 mg/kg Q2 W | 10.0 | 52.5 | 31.0 | NA |
| Fuchs et al. [34] 2018 | KEYNOTE-059 (cohorts 1) | NCT02335411 | Single-arm | II | 259 | Pembrolizumab 200 mg Q3 W. | 11.6 | 27.0 | 23.4 | NA |
| Herbst et al. [35] 2019 | JVDF | NCT02443324 | Single-arm | La/b | 41 | Pembrolizumab 200 mg on day 1 + ramucirumab 10 mg/kg days 1-8. | 7.3 | 51.2 | 30.8 | 12.3 |
| Janjigian et al. [36] 2018 | CheckMate-032 | NCT01928394 | Dose-escalation | I/II | 59 | Nivolumab 3 mg/kg Q2 W. | 12.0 | 32.0 | 39.0 | 8.0 |
| Kelly et al. [37] 2020 | NA | NCT02340975 | RCT | Ib/II | 27 | Durvalumab 20 mg/kg + tremelimumab 1 mg/kg Q4W. | 7.4 | NA | 37.0 | NA |
| Muro et al. [38] 2016 | KEYNOTE-012 | NCT01848834 | Single-arm | Ib | 39 | Pembrolizumab 10 mg/kg Q2 W. | 22.0 | 33.0 | 42.0 | NA |
| Shah et al. [39] 2019 | KEYNOTE-180 | NCT02559687 | Single-arm | II | 121 | Pembrolizumab 200 mg Q3 W. | 9.9 | 30.6 | 28.0 | NA |
| Shitara et al. [39] 2018 | KEYNOTE-061 | NCT02370498 | RCT | III | 592, 296 vs 296 | Pembrolizumab 200 mg Q3 W vs paclitaxel 80 mg/m² daily 1, 8, 15 d of 4-wk cycles | 11.1 | 20.7 | 40.0 | NA |

ORR: Objective response rate; DCR: Disease control rate; OS: Overall survival; PFS: Progression-free survival; RCT: Randomized controlled trial; NA: Not available.

**ORR**

ORR, which is the optimal number of partial responses (PR) or complete responses (CR) divided by the total number of patients receiving treatment, for all 1618 patients was recorded. Overall, the pooled ORR was 15% (95% confidence interval [CI]: 14%-18%, P < 0.001), exhibiting significant heterogeneity (I² = 100%, P < 0.001) (Figure 3). Within subgroup analysis, the pooled ORR for monotherapy was 12% (95%CI: 9%-15%, P < 0.001) and 27% (95%CI: 6%-59%, P < 0.001) for combined therapy.

**DCR**

Only 12 trails including 1591 patients reported DCR, which is the sum of patients diagnosed with complete remission, partial remission, or stable disease. The pooled DCR was 40% (95%CI: 33%-46%, P < 0.001), exhibiting high heterogeneity (I² = 100%, P < 0.001) (Figure 4). Compared to patients in the monotherapy group, patients in the
combination group had a higher DCR (68%, 95% CI: 35%-100% vs 34%, 95% CI: 27%-41%).

**Survival benefits: OS and PFS**

The 6-mo OS of 685 patients in six trials and 6-mo PFS of 708 patients in eight trails were reported. The pooled 6-mo OS and PFS were 54% (95% CI: 45%-64%, \( P < 0.001 \), Figure 5A) and 26% (95% CI: 20%-32%, \( P < 0.001 \), Figure 5B), respectively. Furthermore, the 6-mo OS and PFS of patients in the monotherapy group were 46% (95% CI: 45%-48%, \( P < 0.001 \)) and 21% (95% CI: 17%-26%, \( P < 0.001 \)), respectively, significantly lower than the corresponding OS of 72% (95% CI: 27%-116%, \( P < 0.001 \)) and PFS of 34% (95% CI: 3%-72%, \( P < 0.001 \)) of patients in the combination group. The 12-mo OS and PFS were reported in 11 trials involving 1393 and 4 trials involving 580 patients. The pooled 12-mo OS and PFS were 42% (95% CI: 21%-62%, \( P < 0.001 \), Figure 5C) and 11% (95% CI: 8%-13%, \( P < 0.001 \), Figure 5D). However, contrary to the 6-mo OS and PFS results in the subgroup analysis, the 12-mo OS of patients in the monotherapy group was 43% (95% CI: 21%-66%), significantly higher than that (34%; 95% CI: 28%-40%) of patients in the combination group, while the 12-mo PFS (12%, 95% CI: 11%-14%) of patients in the combination group was only slightly higher than that (10%, 95% CI: 7%-13%) of patients in the monotherapy group.

**PD-L1 expression and ORR**

Of the 1191 patients in nine trials, the ORR was 15% (95% CI: 9%-21%, \( P < 0.001 \), Figure 6A) for patients with positive (≥ 1%) PD-L1 expression and 7% (95% CI: 3%-11%, \( P = 0.001 \), Figure 6B) for patients with negative (≤ 1%) PD-L1 expression. In
addition, the pooled OR was 2.54 (95% CI: 1.56-4.15, \( P < 0.001 \)), indicating that the ORR of PD-L1 positive patients was significantly higher than that of negative patients (Figure 7).

**AEs related to treatment**

Of the 1618 patients included in 13 trials reporting AEs, 869 (53.7%) experienced at least one AE and 237 (14.6%) experienced at least one grade \( \geq 3 \) AE. The overall incidence of any-grade AEs was 64% (95% CI: 54%-73%, \( P < 0.001 \), Figure 8) with significantly more patients under the combination therapy than under monotherapy (84% vs 58%). The total incidence of grade \( \geq 3 \) AEs was 18% (95% CI: 16%-20%, \( P < 0.001 \)). In the monotherapy group, the incidence of grade \( \geq 3 \) AEs was 13% (95% CI: 11%-15%, \( P < 0.001 \)), which was 22% lower than that of the combination therapy group (Figure 9).

The most common any grade AEs was fatigue (15.8%; 95% CI: 11.1%-20.5%), followed by infusion reaction (13.8%; 95% CI: 1.3%-26.3%), pruritus (13.1%; 95% CI: 9.8%-16.4%), decreased appetite (9.6%), nausea (9.4%), abdominal pain (9.3%), diarrhea (8.3%) and pyrexia (8.0%). The most common grade \( \geq 3 \) AEs was abdominal pain (2.8%, 95% CI: -3.4%-9.0%), and the incidence of other common grade \( \geq 3 \) AEs was fairly low (Table 2).

**Publication bias and sensitivity analysis**

Manual removal of any study for sensitivity analysis found no changes and reverse in the forest plot direction of all the results, indicating that the study results are both reliable and stable. Begg and Egger's tests on publication bias showed only presence of bias in 12-mo OS (\( P = 0.015 < 0.05 \)). No publication bias was found in other outcomes (Table 3).
**Table 2 Meta-analysis of common adverse events with anti-PD-1/PD-L1 antibody therapy**

| Common AE            | Any grade (%) | 95%CI     | Grade ≥ 3 (%) | 95%CI     |
|----------------------|---------------|-----------|---------------|-----------|
| Fatigue              | 15.8          | 11.1-20.5 | 1.2           | 0.6-1.9   |
| Infusion reaction    | 13.8          | 1.3-26.3  | 0.6           | -0.2-1.4  |
| Pruritus             | 13.1          | 9.8-16.4  | NA            | NA        |
| Decreased appetite   | 9.6           | 5.7-13.3  | 0.9           | 0.2-1.6   |
| Nausea               | 9.4           | 4.1-14.6  | 1.4           | -2.5-5.4  |
| Abdominal pain       | 9.3           | -9.5-28.1 | 2.8           | -3.4-9.0  |
| Diarrhea             | 8.3           | 4.7-11.8  | 0.6           | 0.2-0.9   |
| Pyrexia              | 8.0           | 1.3-14.6  | NA            | NA        |
| Vomiting             | 7.8           | 0.1-15.4  | NA            | NA        |
| Rash                 | 7.3           | 5.2-9.4   | 0.9           | -0.1-1.8  |
| Arthralgia           | 6.2           | 3.4-9.0   | NA            | NA        |
| Hypothyroidism       | 4.4           | 2.0-6.7   | 0.4           | 0.0-0.9   |
| Elevated AST         | 4.1           | 2.1-6.2   | 1.5           | -0.6-3.5  |
| Asthenia             | 3.2           | 1.3-5.1   | 0.7           | -0.2-1.6  |
| Elevated ALT         | 2.7           | 1.2-4.1   | 0.9           | -0.4-2.1  |
| Pneumonitis          | 2.7           | 0.5-5.4   | 0.5           | 0.1-1.0   |
| Elevated lipase      | 0.9           | -0.4-2.2  | 0.7           | -0.2-1.6  |
| Colitis              | 0.8           | 0.2-1.4   | 0.4           | 0.0-0.8   |

AEs: Adverse events; CI: Confidence interval; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; NA: Not available.

**Table 3 P values of Begg and Egger’s tests**

| Test               | ORR  | DCR  | 6-mo OS | 6-mo PFS | 12-mo OS | 12-mo PFS | AEs   | Grade ≥ 3 AEs |
|--------------------|------|------|---------|----------|----------|-----------|-------|---------------|
| Begg’s P value     | 0.669| 0.945| 0.452   | 0.902    | 0.161    | 0.734     | 0.583 | 0.760         |
| Egger’s P value    | 0.973| 0.890| 0.810   | 0.448    | 0.015    | 0.821     | 0.924 | 0.992         |

ORR: Objective response rate; DCR: Disease control rate; OS: Overall survival; PFS: Progression-free survival; AEs: Adverse events.

**DISCUSSION**

Immunoregulatory therapy has been shown to be effective in the control of advanced cancer. PD-1, a member of the CD28 family, is a receptor expressed on the surface of activated T cells that inhibits their activation and promotes apoptosis[41]. When bound to ligands, PD-1 can activate intracellular signaling pathways and inhibit the activation of immune cells, thereby reducing antibodies and cytokines secreted by immune cells and even depleting immune cells, thus maintaining the homeostasis of the immune system[42]. PD-L1 is the primary ligand of PD-1 and is expressed in certain tumor cells as well as activated B and T cells, dendritic cells, medullary cells, and endothelial cells. The molecule is also expressed in various tumor types and contributes to tumor immune escape[21,41]. The interaction between PD-1 and PD-L1 leads to down-regulation of T cells and their apoptosis and rejection by tumor microenvironment ultimately, which causes cancer cells to evade immune response[43]. Many studies have shown that blocking the interaction between PD-1 and PD-L1 can enhance T cell responses and mediate antitumor activity[44].

Although numerous clinical trials have already confirmed the efficacy of manageable safety of anti-PD-1/PD-L1 therapy in patients with advanced GC/GEJC, so far the FDA has only approved pembrolizumab for advanced GC/GEJC patients[45]. This approval was merely based on KEYNOTE-059, a single-arm clinical
trial, which showed an ORR of 11.6% (95% CI: 0.08-0.161) in Cohort 1, and 25.8% (95% CI: 0.119-0.46) in Cohorts 2 and 3 with a median OS of 20.7 mo (95% CI: 9.2-20.7)\(^2\), 15.5% (95% CI: 10.1-22.4%) for PD-L1 positive patients and 6.4% (95% CI: 2.6%-12.8%) for PD-L1 negative patients\(^3\).

Contrary to the findings of KEYNOTE-059, KEYNOTE-061, which analyzed the different effects between pembrolizumab and paclitaxel in advanced GC/GEJC patients who had been previously treated\(^4\), and JAVELIN Gastric 300, which compared the efficacy and safety of avelumab and paclitaxel or irinotecan in GC/GEJC patients\(^2\), indicated that anti-PD-1/anti-PD-L1 antibody therapy is not significantly superior, in a significant way, to paclitaxel or irinotecan. ATTRACTION-2, the earliest randomized phase 3 study of an immune checkpoint inhibitor in advanced GC/GEJC patients, showed that nivolumab led to prolonged OS than placebo, and exhibited early and durable responses with a manageable safety profile\(^3\)\(^,\)^\(^4\). Additionally, ATTRACTION-4, which studied the safety and efficacy of nivolumab in combination with S-1/capecitabine plus oxaliplatin in patients with previously untreated, unresectable, advanced or recurrent GC/GEJC, confirmed that nivolumab combined with chemotherapy led to manageable safety as well as clinically relevant antitumor activity with a reported ORR of 65.8%, DCR of 84.2%, and median OS over 13.9 mo.

Although the included clinical trials indicated different conclusions regarding the efficacy and safety of immune checkpoint inhibitors for advanced GC/GEJC patients, when combined, as shown in ORR, DCR, 6-mo OS, 6-mo PFS, 12-mo OS, and 12-mo PFS, it is both effective and manageable safe. A total of 15% of patients exhibited either a complete or a PR, and 40% showed progress in disease control. After treatment, 42% of patients survived for more than 1 year, with 26% exhibiting disease stabilities for 6 mo. Moreover, anti-PD-1/anti-PD-L1 antibody therapy also exhibited manageable safety and can, in fact, be tolerated by most patients. The total incidence of any grade AEs was 64%, with signs of fatigue (15.8%), infusion reaction (13.8), and pruritus (13.1%), while that of grade ≥ 3 AEs was 18%, with signs of abdominal pain (2.8%), elevated AST (1.5%), and fatigue (1.2%). Although the immune-related AEs from anti-PD-1/anti-PD-L1 antibody occurred as a consequence of impaired self-tolerance from loss of T-cell inhibition\(^5\), these side effects were generally manageable but can be fatal in some cases. Therefore, doctors should pay close attention to the signs of AE during treatment and take appropriate counter measures. It should be noted that GC/GEJC patients with different PD-L1 levels reacted differently to the anti-PD-1/anti-PD-L1

### Figure 3 Pooled analysis of objective response rate.

| Study or subgroup | Risk difference | SE | Weight | IV, random, 95%CI | Risk difference | SE | Weight | IV, random, 95%CI |
|------------------|----------------|----|--------|-------------------|----------------|----|--------|-------------------|
| 2.5.1 Monotherapy |                |    |        |                   |                |    |        |                   |
| Bang YJ 2018     | 0.022           | 0.001 | 7.9%   | 0.02 [0.02, 0.02] |                |    |        |                   |
| Bang YJ 2019     | 0.258           | 0.014 | 7.3%   | 0.26 [0.23, 0.29] |                |    |        |                   |
| Chen LT 2019     | 0.119           | 0.001 | 7.9%   | 0.12 [0.12, 0.12] |                |    |        |                   |
| Chung HC 2019    | 0.067           | 0.002 | 7.8%   | 0.07 [0.06, 0.07] |                |    |        |                   |
| Doi T 2018       | 0.1             | 0.008 | 7.7%   | 0.10 [0.08, 0.12] |                |    |        |                   |
| Fuchs CS 2018    | 0.116           | 0.001 | 7.9%   | 0.12 [0.11, 0.12] |                |    |        |                   |
| Janjigian YY 2018| 0.12            | 0.006 | 7.7%   | 0.12 [0.11, 0.13] |                |    |        |                   |
| Muro K 2016      | 0.22            | 0.012 | 7.4%   | 0.22 [0.20, 0.24] |                |    |        |                   |
| Shah MA 2019     | 0.099           | 0.002 | 7.8%   | 0.10 [0.10, 0.10] |                |    |        |                   |
| Shitara K 2018   | 0.111           | 0.001 | 7.9%   | 0.11 [0.11, 0.11] |                |    |        |                   |
| Subtotal (95%CI) | 77.3%           | 0.12 [0.09, 0.15] |               |                   |                |    |        |                   |

Heterogeneity: $\tau^2 = 0.00; \chi^2 = 7010.89$, df = 9 ($p < 0.00001$); $I^2 = 100$

Test for overall effect: $Z = 8.66$ ($p < 0.00001$)

### 2.5.2 Combination

| Study or subgroup | Risk difference | SE | Weight | IV, random, 95%CI | Risk difference | SE | Weight | IV, random, 95%CI |
|------------------|----------------|----|--------|-------------------|----------------|----|--------|-------------------|
| Boku N 2019      | 0.658           | 0.012 | 7.4%   | 0.66 [0.63, 0.68] |                |    |        |                   |
| Herbst RS 2019   | 0.073           | 0.006 | 7.7%   | 0.07 [0.06, 0.08] |                |    |        |                   |
| Kelly RJ 2020    | 0.074           | 0.01  | 7.6%   | 0.07 [0.05, 0.09] |                |    |        |                   |
| Subtotal (95%CI) | 22.7%           | 0.27 [0.06, 0.59] |               |                   |                |    |        |                   |

Heterogeneity: $\tau^2 = 0.08; \chi^2 = 2005.72$, df = 2 ($p < 0.00001$); $I^2 = 100$

Test for overall effect: $Z = 1.61$ ($p = 0.11$)

### Total (95%CI)

| Risk difference | SE | Weight | IV, random, 95%CI | Risk difference | SE | Weight | IV, random, 95% CI |
|-----------------|----|--------|-------------------|----------------|----|--------|-------------------|
| 100.0%          | 0.15 [0.13, 0.18] |           |                   |                |    |        |                   |

Heterogeneity: $\tau^2 = 0.00; \chi^2 = 9249.21$, df = 12 ($p < 0.00001$); $I^2 = 100$

Test for overall effect: $Z = 11.01$ ($p < 0.00001$)

Test for subgroup differences: $\chi^2 = 0.77$, df = 1 ($p = 0.38$), $I^2 = 0$.\(^4\)
Antibody therapy: Patients with PD-L1 overexpression achieved better clinical efficacy, as their ORR was 15% compared with only 7% for PD-L1 negative patients, consistent with a previous study.[24]. The Cancer Genome Atlas (TCGA) classifies gastric adenocarcinoma into four molecular subtypes: Epstein-Barr virus positive (EBV+), microsatellite instability-high (MSI-H), genomically stable, or chromosomal instability[23]. MSI-H is associated with high PD-L1 tumor expression, therefore making tumor more sensitive to immunotherapy[48, 49]. Consistently, PD-L1 expression has been related to OS[50]. Additionally, a recent meta-analysis also indicated that EBV and MSI subtypes tended to express PD-L1, thus enabling PD-L1 to act as a potential screening predictor for screening for EBV and MSI subtype GC patients.

Monotherapy vs combination therapy analysis showed that while the ORR (27%), DCR (68%), 6-mo OS (72%), and 6-mo PFS (34%) of the combination therapy group were higher than those of the monotherapy group, the incidence rate of AEs was also higher, with 84% for any grade AEs and 35% for grade ≥ 3 AEs. A study in a melanoma mouse model also showed that the combined use of PD-1 inhibitors and TNF-α inhibitors has a better therapeutic effect than treatment with PD-1 inhibitors alone[51]. Thus, for patients who experienced reduced clinical efficacy, combination therapy may be a more potent option, although doctors should pay more attention to the potential development of AEs as well as the treatment progress of the pre-treated patients.

The efficacy and safety of combinational anti-PD-1/anti-PD-L1 antibody therapy still need to be explored. At present, only four trials were eligible to be included in this study, namely, KEYNOTE-590 (NCT03189719), CheckMate 649 (NCT02872116), KEYNOTE-062 (NCT02494583), and JAVELIN Gastric 100 (NCT02625610), which are all phase 3 clinical trials[30, 35, 37]. Notably, camrelizumab, a PD-1 inhibitor developed by Jiangsu Hengrui Medicine Co. Ltd., received approval in China in May 2019, although only conditionally for those who have already undergone at least two systemic chemotherapies for either relapsed or refractory classical Hodgkin lymphoma[52]. Additionally, two other phase 3 clinical trials on the efficacy and safety of camrelizumab combined with other chemotherapy drugs, NCT03691090 and NCT03813784, are under way.

To be noted, despite the use of subgroup analysis and random effect model, our study is limited to the inherent heterogeneity of the included studies, in terms of both type and dosage of the drugs although publication bias was not found in most of the
### A

| Study or subgroup | Risk difference | SE  | Weight | IV, random, 95%CI | Risk difference | SE  | Weight | IV, random, 95%CI |
|------------------|-----------------|-----|--------|-------------------|-----------------|-----|--------|-------------------|
| **2.2.1 Monotherapy** |                 |     |        |                   |                 |     |        |                   |
| Bang YJ 2018     | 0.41            | 0.003| 16.7%  | 0.41 [0.40, 0.42]  |                 |     |        |                   |
| Fuchs CS 2018    | 0.465           | 0.001926| 16.7%  | 0.47 [0.46, 0.47]  |                 |     |        |                   |
| Muro K 2016      | 0.465           | 0.002| 16.7%  | 0.47 [0.46, 0.47]  |                 |     |        |                   |
| Shah MA 2019     | 0.49            | 0.012| 16.6%  | 0.49 [0.47, 0.51]  |                 |     |        |                   |
| **Subtotal (95%CI)** | 66.7%           | 0.46 [0.43, 0.48] |                   |                 |     |        |                   |
| Heterogeneity: 
  Tau² = 0.00; 
  Chi² = 285.16, df = 3 (P < 0.000001); I² = 99% |
| Test for overall effect: Z = 33.76 (P < 0.000001) |

| **2.2.2 Combination** |                 |     |        |                   |                 |     |        |                   |
| Boku N 2019       | 0.946           | 0.006| 16.7%  | 0.95 [0.93, 0.96]  |                 |     |        |                   |
| Herbst RS 2019    | 0.49            | 0.012193| 16.6%  | 0.49 [0.47, 0.51]  |                 |     |        |                   |
| **Subtotal (95%CI)** | 33.3%           | 0.72 [0.27, 1.16] |                   |                 |     |        |                   |
| Heterogeneity: 
  Tau² = 0.10; 
  Chi² = 1125.99, df = 1 (P < 0.000001); I² = 100% |
| Test for overall effect: Z = 3.15 (P = 0.002) |
| Test for subgroup differences: 
  Chi² = 1.32, df = 1 (P = 0.25), I² = 24.0% |

### B

| Study or subgroup | Risk difference | SE  | Weight | IV, random, 95%CI | Risk difference | SE  | Weight | IV, random, 95%CI |
|------------------|-----------------|-----|--------|-------------------|-----------------|-----|--------|-------------------|
| **2.1.1 Monotherapy** |                 |     |        |                   |                 |     |        |                   |
| Bang YJ 2019     | 0.349           | 0.015| 12.2%  | 0.35 [0.32, 0.38]  |                 |     |        |                   |
| Chung HC 2019    | 0.173           | 0.003| 12.6%  | 0.17 [0.17, 0.18]  |                 |     |        |                   |
| Fuchs CS 2018    | 0.141           | 0.001| 12.6%  | 0.14 [0.14, 0.14]  |                 |     |        |                   |
| Muro K 2016      | 0.26            | 0.003| 12.6%  | 0.26 [0.25, 0.27]  |                 |     |        |                   |
| Shah MA 2019     | 0.16            | 0.003| 12.6%  | 0.16 [0.15, 0.17]  |                 |     |        |                   |
| **Subtotal (95%CI)** | 62.7%           | 0.21 [0.17, 0.26] |                   |                 |     |        |                   |
| Heterogeneity: 
  Tau² = 0.00; 
  Chi² = 1626.17, df = 4 (P < 0.000001); I² = 100% |
| Test for overall effect: Z = 8.87 (P < 0.000001) |

| **2.1.2 Combination** |                 |     |        |                   |                 |     |        |                   |
| Boku N 2019       | 0.709           | 0.011| 12.4%  | 0.71 [0.69, 0.73]  |                 |     |        |                   |
| Herbst RS 2019    | 0.26            | 0.011| 12.4%  | 0.26 [0.24, 0.28]  |                 |     |        |                   |
| Kelly RJ 2020     | 0.061           | 0.009| 12.5%  | 0.06 [0.04, 0.08]  |                 |     |        |                   |
| **Subtotal (95%CI)** | 37.3%           | 0.34 [-0.03, 0.72] |                   |                 |     |        |                   |
| Heterogeneity: 
  Tau² = 0.11; 
  Chi² = 2100.57, df = 2 (P < 0.000001); I² = 100% |
| Test for overall effect: Z = 1.78 (P = 0.07) |
| Total (95%CI) | 100.0% | 0.26 [0.20, 0.32] |                   |                 |     |        |                   |
| Heterogeneity: 
  Tau² = 0.01; 
  Chi² = 4342.64, df = 7 (P < 0.000001); I² = 100% |
| Test for overall effect: Z = 8.77 (P < 0.000001) |
| Test for subgroup differences: 
  Chi² = 0.44, df = 1 (P = 0.51), I² = 0% |
CONCLUSION

Anti-PD-1/anti-PD-L1 antibody therapy is an effective treatment option with manageable AEs and high ORR for advanced GC/GEJC patients with overexpression.
Figure 6 Objective response rate of PD-L1 positive (A) and negative patients (B).

of PD-L1. Furthermore, under the premise of paying close attention to safety of the treatment, it offers even better efficacy in combination with chemotherapy.
2.12.1 monotherapy

| Study or subgroup | Experimental | Control | Odds ratio | Odds ratio |
|-------------------|--------------|---------|------------|------------|
|                   | Events       | Total   | Weight     | M-H. random. 95%CI | M-H. random. 95%CI |
| Bang YJ 2018      | 2            | 46      | 2 111 6.0% | 2.48 [0.34, 18.14] |  |
| Chung HC 2019     | 2            | 26      | 2 51 5.9%  | 2.04 [0.27, 15.39] |  |
| Doi T 2018        | 3            | 11      | 1 27 4.2%  | 9.75 [0.89, 107.26] |  |
| Fuchs CS 2018     | 23           | 148     | 7 109 30.5% | 2.68 [1.11, 6.50] |  |
| Janjigian YY 2018 | 3            | 16      | 3 26 7.9%  | 1.77 [0.31, 10.07] |  |
| Shah MA 2019      | 8            | 58      | 4 63 15.1% | 2.36 [0.67, 8.30]  |  |
| Shitara K 2018    | 31           | 196     | 2 99 11.4% | 9.11 [2.13, 38.91] |  |
| Subtotal (95%CI)  | 501          | 486     | 81.0%      | 3.11 [1.80, 5.35]  |  |

Total events 72 21
Heterogeneity: Tau² = 0.00; Chi² = 4.06, df = 6 (P = 0.67); I² = 0%
Test for overall effect: Z = 4.09 (P < 0.0001)

2.12.2 combination

| Study or subgroup | Experimental | Control | Odds ratio | Odds ratio |
|-------------------|--------------|---------|------------|------------|
|                   | Events       | Total   | Weight     | M-H. random. 95%CI | M-H. random. 95%CI |
| Boku N 2019       | 2            | 4       | 10 17 5.0% | 0.70 [0.08, 6.22]  |  |
| Herbst RS 2019    | 9            | 22      | 6 17 14.0% | 1.27 [0.34, 4.70]  |  |
| Subtotal (95%CI)  | 26           | 34      | 19.0%      | 1.08 [0.35, 3.33]  |  |

Total events 11 16
Heterogeneity: Tau² = 0.00; Chi² = 0.21, df = 1 (P = 0.65); I² = 0%
Test for overall effect: Z = 0.14 (P = 0.89)
Test for subgroup differences: Chi² = 2.74, df = 1 (P = 0.10), I² = 63.5%

Figure 7 Comparison of objective response rate between PD-L1 positive and negative patients.

| Study or subgroup | Risk difference | SE  | Weight | Risk difference | SE  | Weight |
|-------------------|-----------------|-----|--------|-----------------|-----|--------|
| Bang YJ 2018      | 0.486           | 0.003 | 7.7%   | 0.490           | 0.048 | 0.49 |  |
| Bang YJ 2019      | 0.774           | 0.013 | 7.7%   | 0.770           | 0.075 | 0.80 |  |
| Chen LT 2019      | 0.43            | 0.002 | 7.7%   | 0.430           | 0.430 | 0.43 |  |
| Chung HC 2019     | 0.207           | 0.003 | 7.7%   | 0.207           | 0.200 | 0.21 |  |
| Doi T 2018        | 0.185           | 0.017 | 7.7%   | 0.180           | 0.780 | 0.82 |  |
| Fuchs CS 2018     | 0.602           | 0.002 | 7.7%   | 0.600           | 0.600 | 0.61 |  |
| Janjigian YY 2018 | 0.69            | 0.008 | 7.7%   | 0.690           | 0.670 | 0.71 |  |
| Muro K 2016       | 0.67            | 0.012 | 7.7%   | 0.670           | 0.650 | 0.69 |  |
| Shah MA 2019      | 0.57            | 0.004 | 7.7%   | 0.570           | 0.570 | 0.59 |  |
| Shitara K 2018    | 0.53            | 0.002 | 7.7%   | 0.530           | 0.530 | 0.53 |  |
| Subtotal (95%CI)  |                 |      |        | 77.0%           | 0.580 | 0.49 | 66.6

Heterogeneity: Tau² = 0.02; Chi² = 160.88, df = 9 (P < 0.00001); I² = 100%
Test for overall effect: Z = 13.40 (P < 0.00001)

2.7.2 Combination

| Study or subgroup | Risk difference | SE  | Weight | Risk difference | SE  | Weight |
|-------------------|-----------------|-----|--------|-----------------|-----|--------|
| Boku N 2019       | 0.975           | 0.004 | 7.7%   | 0.970           | 0.970 | 0.98 |  |
| Herbst RS 2019    | 0.829           | 0.009 | 7.7%   | 0.810           | 0.810 | 0.85 |  |
| Kelly RJ (95%CI)  | 0.704           | 0.017 | 7.6%   | 0.700           | 0.670 | 0.74 |  |
| Subtotal (95% CI) |                 |      |        | 23.0%           | 0.840 | 0.69 | 98.9

Heterogeneity: Tau² = 0.02; Chi² = 421.39, df = 2 (P < 0.00001); I² = 100%
Test for overall effect: Z = 11.44 (P < 0.00001)
Test for subgroup differences: Chi² = 9.41, df = 1 (P = 0.002), I² = 89.4%

Figure 8 Pooled rate of any grade adverse events.
Yang L et al. Anti-PD-1/anti-PD-L1 antibody therapy in advanced GC/GEJC

WJGO https://www.wjgnet.com 1360 November 15, 2020 Volume 12 Issue 11

ARTICLE HIGHLIGHTS

Research background
Many clinical trials have confirmed that advanced gastric cancer or gastroesophageal junction cancer (GC/GEJC) patients can benefit from anti-PD-1/anti-PD-L1 antibody therapy. In addition, Epstein-Barr virus and microsatellite instability subtype gastric cancer patients tend to have high PD-L1 expression. Therefore, anti-PD-1/anti-PD-L1 antibody therapy may become a potential treatment for advanced GC/GEJC patients.

Research motivation
To better assess the efficacy and safety of anti-PD-1/anti-PD-L1 antibody therapy, we integrated data from 13 eligible studies for a systematic review and meta-analysis.

Research objectives
The purpose of this meta-analysis was to clarify the efficacy and safety of anti-PD-1/anti-PD-L1 antibody therapy in advanced GC/GEJC patients.

Research methods
PubMed, Web of Science, Cochrane Library, and EMBASE databases were searched to extract relevant data according to the designed extraction scheme, and conduct statistical analysis using Review Manger 5.3 and STATA 14.0 software. The main outcomes of this study included the objective response rate (ORR), disease control rate (DCR), overall survival (OS), free survival (PFS), and adverse events (AEs).

Research results
Our meta-analysis showed that the combined ORR and DCR were 15% (95%CI: 14%-18%) and 40% (95%CI: 33%-46%), respectively. The combined 6-mo OS and PFS were 54% (95%CI: 45%-64%) and 26% (95%CI: 20%-32%) respectively, and the 12-mo OS and PFS were 42% (95%CI: 21%-62%) and 11% (95%CI: 8%-13%), respectively. In addition, the incidence of any grade AEs and ≥ 3 grade AEs was 64% (95%CI: 54%-73%) and 18% (95%CI: 16%-20%), respectively.

Figure 9  Pooled rate of grade ≥ 3 adverse events.
Research conclusions
Anti-PD-1/anti-PD-L1 antibody therapy has good anti-tumor efficacy with manageable AEs in advanced GC/GEJC patients. In addition, under the premise of paying close attention to safety of the treatment, it offers even better efficacy in combination with chemotherapy.

Research perspectives
This meta-analysis demonstrated the efficacy and safety of anti-PD-1/anti-PD-L1 antibody therapy and high ORR for advanced GC/GEJC patients with overexpression of PD-L1. Furthermore, when paying close attention to the safety of treatment, it seems that combination with conventional chemotheraphy treatment can achieve better clinical efficacy. This study has some limitations. The future research direction can be to verify the efficacy and safety of anti-PD-1/anti-PD-1 antibody combined with chemotheraphy in patients with advanced GC/GEJC.

REFERENCES
1 Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018; 68: 394-424 [PMID: 30207593 DOI: 10.3322/caac.21402]
2 Ang TL, Fock KM. Clinical epidemiology of gastric cancer. Singapore Med J 2014; 55: 621-628 [PMID: 25636323 DOI: 10.1162/smedj.2014174]
3 den Hoed CM, Kuipers EJ. Gastric Cancer: How Can We Reduce the Incidence of this Disease? Curr Gastroenterol Rep 2016; 18: 34 [PMID: 27184043 DOI: 10.1007/s11894-016-0560-6]
4 Luo G, Zhang Y, Guo P, Wang L, Huang Y, Li K. Global patterns and trends in stomach cancer incidence: Age, period and birth cohort analysis. Int J Cancer 2017; 141: 1333-1344 [PMID: 28614909 DOI: 10.1002/ijc.30835]
5 Neckela L, Matei L, Draga D, Neagu AI, Mambet C, Nedeianu S, Bleotu C, Diaconu CC, Chivu-Economescu M. Recent advances in gastric cancer early diagnosis. World J Gastroenterol 2019; 25: 2029-2044 [PMID: 31114311 DOI: 10.3748/wjg.v25.i17.2029]
6 Ajani JA. Gastroesophageal cancers: progress and problems. J Natl Compr Canc Netw 2008; 6: 813-814 [PMID: 18998257 DOI: 10.1004/jnccn.2008.0061]
7 Fontana E, Smyth EC. Novel targets in the treatment of advanced gastric cancer: a perspective review. Ther Adv Med Oncol 2016; 8: 113-125 [PMID: 26929787 DOI: 10.1177/1758835915616935]
8 Venerito M, Link A, Roikas T, Malfertheiner P. Review: Gastric cancer-Clinical aspects. Helicobacter 2019; 24 Suppl 1: e12643 [PMID: 31486238 DOI: 10.1111/hed.12643]
9 Dittmar Y, Settmacher U. Individualized treatment of gastric cancer: Impact of molecular biology and pathohistological features. World J Gastrointest Oncol 2015; 7: 292-302 [PMID: 26609299 DOI: 10.4253/wjgo.v7.i11.292]
10 Smyth EC, Verheij M, Allum W, Cunningham D, Cervantes A, Arnold D; ESMO Guidelines Committee. Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2016; 27: v38-v49 [PMID: 27664260 DOI: 10.1093/annonc/mdw350]
11 Goede EF, Smyth EC. Immunotherapy for Gastroesophageal Cancer. J Clin Med 2016; 5 [PMID: 27669318 DOI: 10.3390/jcm5190084]
12 Ajani JA, D’Amico TA, Almahanna K, Bentrem DJ, Chao J, Das P, Denlinger CS, Fanta P, Farjah F, Fachs CS, Gerdes H, Gibson M, Glasgow BE, Hayman JA, Hochwald S, Hofstetter WL, Ilson DH, Jaroszewski D, Johung KL, Keswani RN, Kleinberg LR, Korn WM, Leong S, Linn C, Lockhart AC, Ly QP, Mulcahy MF, Orringer MB, Perry KA, Poulsides GA, Scott WJ, Strong VE, Washington MK, Weksler B, Willett CG, Wright CD, Zelman D, McMillian N, Sundar H. Gastric Cancer, Version 3.2016, NCCN Clinical Practice Guidelines. J Natl Compr Canc Netw 2016; 14: 1286-1312 [PMID: 27697982 DOI: 10.6004/jnccn.2016.0137]
13 Ford HE, Marshall A, Bridgewater JA, Janowitz T, Coxon FY, Wadsley J, Mansoor W, Fyfe D, Madhusudan S, Middleton GW, Swinson D, Falk S, Chau I, Cunningham D, Kareelas P, Cook N, Blazeby JM, Dunn JA; COUGAR-02 Investigators. Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial. Lancet Oncol 2014; 15: 78-86 [PMID: 24332238 DOI: 10.1016/S1470-2045(13)70549-7]
14 Smyth EC, Moelker M. Late-line treatment in metastatic gastric cancer: today and tomorrow. Ther Adv Med Oncol 2011; 3: 56-61 [PMID: 21489035 DOI: 10.1177/1758859111406522]
15 Sharma P, Allison JP. The future of immune checkpoint therapy. Science 2015; 348: 56-61 [PMID: 25838737 DOI: 10.1126/science.aab8172]
16 Hayashi H, Nakagawa K. Combination therapy with PD-1 or PD-L1 inhibitors for cancer. Int J Clin Oncol 2020; 25: 818-830 [PMID: 31549270 DOI: 10.1007/s11709-019-01548-0]
17 Dong Y, Sun Q, Zhang X. PD-1 and its ligands are important immune checkpoints in cancer. Oncotarget 2017; 8: 2171-2186 [PMID: 27974609 DOI: 10.18632/oncotarget.13895]
18 Alsaab HO, Sau S, Alzhrani R, Tati paradise K, Bhise K, Kashaw SK, Iyer AK. PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome. Front Pharmacol 2017; 8: 561 [PMID: 28876676 DOI: 10.3389/fphar.2017.00561]
Yang L et al. Anti-PD-1/anti-PD-L1 antibody therapy in advanced GC/GEJC

R, Kudchadkar RR, Smylie M, Meyer N, Mortier L, Atkins MB, Long GV, Bhatia S, Lebbé C, Rutkowski P, Yokota K, Yamazaki N, Kim TM, de Prié V, Sabater J, Qureshi A, Larkin J, Ascarierto PA; CheckMate 238 Collaborators. Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma. *N Engl J Med* 2017; 377: 1824-1835 [PMID: 28891423 DOI: 10.1056/NEJMoa1701970]

20 Cancer Genome Atlas Research Network. Comprehensive molecular characterization of gastric adenocarcinoma. *Nature* 2014; 513: 202-209 [PMID: 25079317 DOI: 10.1038/nature13490]

21 Zhang M, Dong Y, Liu H, Wang Y, Zhao S, Xuan Q, Wang Y, Zhang Q. The clinicopathological and prognostic significance of PD-L1 expression in gastric cancer: a meta-analysis of 10 studies with 1,901 patients. *Sci Rep* 2016; 6: 37939 [PMID: 27892511 DOI: 10.1038/srep37939]

22 Li J, Chen L, Xiong Y, Zheng X, Xie Q, Zhou Q, Shi L, Wu C, Jiang J, Wang H. Knockdown of PD-L1 in Human Gastric Cancer Cells Inhibits Tumor Progression and Improves the Cytotoxic Sensitivity to CIK Therapy. *Cell Physiol Biochem* 2017; 41: 907-920 [PMID: 28222426 DOI: 10.1159/000460509]

23 Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Pardoll DM, Brdell DL, Carvajal RD, Lyden A, McDermott D, Weber JS, Mateucci M, Schwartzentruber DJ,随时 R, O'Sheaa J, Kauh J, Odumsi K, Pitot HC, Hamid O, Bhatia S, Martins R, Eaton K, Chen S, Salay TM, Alaparthy S, Grosso JF, Korman AJ, Parker SM, Agrawal S, Goldberg SM, Pardoll DM, Gupta A, Wigginton JM. Safety and activity of anti-PD-1/L1 antibody in patients with advanced cancer. *N Engl J Med* 2012; 366: 2455-2465 [PMID: 22658128 DOI: 10.1056/NEJMoa1206094]

24 Bagley SJ, Baum JM, Langer CJ. PD-1/PD-L1 immune checkpoint blockade in non-small cell lung cancer. *Clin Adv Hematol Oncol* 2015; 13: 676-683 [PMID: 27058572]

25 Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *Int J Surg* 2010; 8: 336-341 [PMID: 20171363 DOI: 10.1016/j.ijsu.2010.02.007]

26 Higgins JP, Altman DG, Gatschke PC, Jini P, Moher D, Oxman AD, Savovic J, Schulz KF, Weeks L, Sterne JA; Cochrane Bias Methods Group; Cochrane Statistical Methods Group. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. *BMJ* 2011; 343: d5928 [PMID: 22008217 DOI: 10.1136/bmj.d5928]

27 Cumpston M, Li T, Page MJ, Chandler J, Welch VA, Higgins JP, Thomas J. Updated guidance for trusted systematic reviews: a new edition of the Cochrane Handbook for Systematic Reviews of Interventions. *Cochrane Database Syst Rev* 2019; 10: ED001412 [PMID: 31643080 DOI: 10.1002/14651858.ED001412]

28 Bang YJ, Ruiz EY, Van Cutsem E, Lee KW, Wyrwicz L, Schenker M, Alisina M, Rya MH, Chung HC, Esquesse L, Al-Batran SE, Park SH, Lichtenis M, Boku N, Moehler MH, Hong J, Xiong H, Hallwachs R, Conti I, Taieb J. Phase III, randomised trial of avelumab versus physician's choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro-esophageal junction cancer: primary analysis of JAVELIN Gastric 300. *Ann Oncol* 2018; 29: 2052-2060 [PMID: 30052729 DOI: 10.1093/annonc/mdy264]

29 Bang YJ, Kang YK, Catanecci DV, Muro K, Fuchs CS, Geva R, Hara H, Golan T, Garrido M, Jalal SI, Borg C, Doi T, Yoon HH, Savage MJ, Wang J, Dalal RP, Shah S, Wainberg ZA, Chung HC. Pembrolizumab alone or in combination with chemotherapy as first-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma: results from the phase II nonrandomized KEYNOTE-059 study. *Gastric Cancer* 2019; 22: 828-837 [PMID: 30911859 DOI: 10.1007/s10120-018-0909-9]

30 Boku N, Rya MH, Kato K, Chung HC, Minashi K, Lee KW, Cho H, Kang WK, Komatsu Y, Tsuda M, Yamaguchi K, Hara H, Fumita S, Azuma M, Chen LT, Kang YK. Safety and efficacy of nivolumab in combination with S1/capcitabine plus oxaliplatin in patients with previously untreated, untreated, or recurrent gastric/gastroesophageal junction cancer: interim results of a randomized, phase II trial (ATTRACTION-4). *Ann Oncol* 2019; 30: 250-258 [PMID: 30566590 DOI: 10.1093/annonc/mdy540]

31 Chen LT, Satoh T, Rya MH, Chao Y, Kato K, Chung HC, Chen JS, Muro K, Kang WK, Yeh KH, Yoshitaka K, Oh SC, Bai L, Tamura T, Lee KW, Hamamoto Y, Kim JC, Chin K, Oh DY, Minashi K, Cho JY, Tsuda M, Samushima H, Kang YK, Boku N. A phase 3 study of nivolumab in previously treated advanced gastric or gastroesophageal junction cancer (ATTRACTION-2) - 2-year update data. *Gastric Cancer* 2020; 23: 510-519 [PMID: 31863227 DOI: 10.1002/14651858.ED000142]

32 Chung HC, Arkenau HT, Lee J, Rha SY, Oh DY, Wyrwicz L, Kang YK, Lee KW, Infante JR, Lee SS, Kemeny M, Keilholz U, Melicar B, Mita A, Plummer R, Smith D, Gelb AB, Xiong H, Hong J, Chang V, Safran V. Avelumab (anti-PD-L1) as first-line switch-maintenance or second-line therapy in patients with advanced gastric or gastroesophageal junction cancer: phase 3b results from the JAVELIN Solid Tumor trial. *J Immunother Cancer* 2019; 7: 30 [PMID: 30717797 DOI: 10.1186/s40425-019-0304-7]

33 Doi T, Iwasa S, Muro K, Satoh T, Hironaka S, Eki T, Bashima N, Hirashita T, Hara H, Machida N, Komatsu Y, Shimada Y, Otta S, Shimizu S, Watanabe M. Phase 1 trial of avelumab (anti-PD-L1) in Japanese patients with advanced solid tumors, including dose expansion in patients with gastric or gastroesophageal junction cancer: the JAVELIN Solid Tumor JPN trial. *Gastric Cancer* 2019; 22: 817-827 [PMID: 30515672 DOI: 10.1002/14651858.ED000142]

34 Fuchs CS, Doi T, Jang RW, Muro K, Satoh T, Machado M, Sun W, Jalal SI, Sham MA, Metges JP, Garrido M, Golan T, Mandala M, Wainberg ZA, Catanecci DV, Ohtsu A, Shirata K, Geva R, Bleeker J, Ko AH, Ku G, Philip P, Enzinger PC, Bang YJ, Leidvan D, Wang J, Rosales M, Dalal RP, Yoon HH. Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer: Phase 2 Clinical KEYNOTE-059 Trial. *JAMA Oncol* 2018; 4: e180013 [PMID: 29545392 DOI: 10.1001/jamaoncol.2018.0013]

35 Herbst RS, Arkenau HT, Santiago-Davila R, Calvo E, Paz-Ares L, Cassier PA, Bendell J, Penel N, Krebs MG, Martin-Liberal J, Isambert N, Soriano A, Wernike M, Cultrera J, Gao L, Widad RC, Mi G, Jin J, Ferry D, Fuchs CS, Petrylak DP, Chau I. Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-esophageal cancer, or urothelial carcinomas (JAVELIN): a multicohort, non-randomised, open-label, phase 1a/b trial. *Lancet Oncol* 2019; 20: 1109-1123 [PMID: 31301962 DOI: 10.1016/S1470-2045(19)30458-9]

36 Janjigian YY, Bendell J, Calvo E, Kim JW, Ascarierto PA, Sharma P, Ott PA, Peltola K, Jaeger D, Evans J, de Braud F, Chau I, Harbison CT, Dorange C, Tsichaki M, Le DT. CheckMate-032 Study: Efficacy and
Safety of Nivolumab and Nivolumab Plus Ipilimumab in Patients With Metastatic Esophageogastric Cancer. J Clin Oncol 2018; 36: 2836-2844 [PMID: 30101914 DOI: 10.1200/JCO.2017.76.6212]

Kelly RJ, Lee J, Bang YJ, Almahanna K, Blum-Murphy M, Catenacci DVT, Chung HC, Wainberg ZA, Gibson MK, Lee KW, Bendell JC, Dentlinger CS, Chee CE, Omori T, Leidner R, Lenz HJ, Chao Y, Rebello MC, Broshawn PZ, He P, McDevitt J, Sheth S, Englert JM, Ku GY. Safety and Efficacy of Durvalumab and Tremelimumab Alone or in Combination in Patients with Advanced Gastric and Gastroesophageal Junction Adenocarcinoma. Clin Cancer Res 2020; 26: 846-854 [PMID: 31676670 DOI: 10.1158/1078-0432.CCR-19-2443]

Muro K, Chung HC, Shankaran V, Geva R, Catenacci D, Gupta S, Eder JP, Golan T, Le DT, Burtness B, McRee AJ, Lin CC, Pathiraja K, Lunceford J, Emancipator K, Juco J, Koshiji M, Bang YJ. Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial. Lancet Oncol 2016; 17: 717-726 [PMID: 27157491 DOI: 10.1016/S1470-2045(16)00175-3]

Shah MA, Kojima T, Hochhauser D, Enzinger P, Rainboujour J, Hollebecque A, Lordick F, Kim SB, Tajika M, Kim HT, Lockhart AC, Arakenua HT, El-Hajbi F, Gupta M, Pfeiffer P, Liu Q, Lunceford J, Kang SP, Bhagia P, Kato K. Efficacy and Safety of Pembrolizumab for Heavytreated Patients With Advanced, Metastatic Adenocarcinoma or Squamous Cell Carcinoma of the Esophagus: The Phase 2 KEYNOTE-180 Study. JAMA Oncol 2019; 5: 546-550 [PMID: 30570649 DOI: 10.1001/jamaoncol.2018.5441]

Shitara K, Özgüroğlu M, Bang YJ, Di Bartolomeo M, Mandalà M, Ryu MH, Forleno L, Olesinski T, Caglević C, Chung HC, Muro K, Goekkurtt E, Mansoor W, McDermott RS, Shacham-Shmueli E, Chen X, Mayo C, Kang SP, Ohtsu A, Fuchs CS; KEYNOTE-061 investigators. Pembrolizumab for heavily pretreated patients with advanced, refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-1). J Biomed Sci 2019; 26: 123-133 [PMID: 29980231 DOI: 10.1007/s40265-019-01167-0]

Zou W, Wolchok JD, Chen L. PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations. Sci Transl Med 2016; 8: 328rv4 [PMID: 26936508 DOI: 10.1126/scitranslmed.aad7118]

Jiang X, Wang J, Deng X, Xiong F, Ge J, Xiang B, Wu X, Ma J, Zhou M, Li X, Li Y, Li G, Xiong W, Guo C, Zeng Z. Role of the tumor microenvironment in PD-L1/PD-1-mediated tumor immune escape. Mol Cancer 2019; 18: 10 [PMID: 30649012 DOI: 10.1186/s12943-018-0928-4]

Iwai Y, Haminishi J, Channoto K, Honjo T. Cancer immunotherapies targeting the PD-1 signaling pathway. J Biomed Sci 2017; 24: 26 [PMID: 28376884 DOI: 10.1186/s12929-017-0329-9]

Dermani FK, Samadi P, Rahmani G, Kohlan AK, Najafi R. PD-L1/PD-1 immune checkpoint: Potential target for cancer therapy. J Cell Physiol 2019; 234: 1313-1325 [PMID: 30191996 DOI: 10.1002/jcp.23717]

Fashoyin-Aje L, Donoghue M, Chen H, He K, Veeraraghavan J, Goldberg KB, Keegan P, McKey AE, Pazdur R. FDA Approval Summary: Pembrolizumab for Recurrent Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing PD-L1. Oncologist 2019; 24: 103-109 [PMID: 30210163 DOI: 10.1634/theoncologist.2018-0221]

Kang YK, Boku N, Satoh T, Ryu MH, Chao Y, Kato K, Chung HC, Chen JS, Muro K, Kang WK, Yeh KH, Yoshikawa T, Oh SC, Bai LY, Tamura T, Lee KW, Hamamoto Y, Kim JG, Chin K, Oh DY, Minashi K, Cho JY, Tsuda M, Chen LT. Nivolumab in patients with advanced gastric or gastroesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2017; 389: 2461-2471 [PMID: 28993052 DOI: 10.1016/S0140-6736(17)31827-5]

Spain L, Dienm S, Larkin J. Management of toxicities of immune checkpoint inhibitors. Cancer Treat Rem 2016; 44: 51-60 [PMID: 26874776 DOI: 10.1097/CTM.0000000000000688]

Dudley JC, Lin MT, Le DT, Eshleman JR. Microsatellite Instability as a Biomarker for PD-L1 Blockade. Clin Cancer Res 2016; 22: 813-820 [PMID: 26880610 DOI: 10.1158/1078-0432.CCR-15-1678]

Ma C, Patel K, Singhi AD, Ren B, Zhu B, Shaikh F, Sun W. Programmed Death-Ligand 1 Expression Is Common in Gastric Cancer Associated With Epstein-Barr Virus or Microsatellite Instability. Am J Surg Pathol 2016; 40: 1496-1506 [PMID: 27465786 DOI: 10.1097/PAS.0000000000000698]

Gu L, Chen M, Guo D, Zhu H, Zhang W, Pan J, Zhong X, Li X, Qian H, Wang X. PD-L1 and gastric cancer prognosis: A systematic review and meta-analysis. PLoS One 2017; 12: e0182692 [PMID: 28796808 DOI: 10.1371/journal.pone.0182692]

Bertrand F, Montfort A, Marchateau E, Imbert C, Gilhodes J, Filleron T, Rochais P, Andreico-Abadie N, Levade T, Meyer N, Colacios C, Séguí B. TNFα blockade overcomes resistance to anti-PD-L1 in experimental melanoma. Nat Commun 2017; 8: 2256 [PMID: 29273790 DOI: 10.1038/s41467-017-02358-7]

Markham A, Keam SJ. Canrelizumab: First Global Approval. Drugs 2019; 79: 1355-1361 [PMID: 31310988 DOI: 10.1007/s40265-019-01167-0]
